Maomeng Tong
Principal
Dr. Maomeng Tong has nearly 15 years’ experience in healthcare industry in China and the U.S., including investment, management consulting and R&D. At INCE Capital, he focuses on investment in healthcare sectors, including biotech, medtech and health tech companies with cutting-edge innovative and revolutionizing technologies. He has led the investment in Allorion Therapeutics and Bennu Biotherapeutics.
Prior to INCE, he was with KKR, responsible for the investment and operation improvement of its healthcare portfolios. He has also worked at McKinsey & Company as the core member of its Greater China healthcare practice, where he served leading pharmaceutical companies and hospital groups on strategic and operation improvement topics.
Dr. Tong holds a Ph.D. in Medical Pharmacology from David Geffen School of Medicine at University of California, Los Angeles, and a B.S. from Tsinghua University.
Prior to INCE, he was with KKR, responsible for the investment and operation improvement of its healthcare portfolios. He has also worked at McKinsey & Company as the core member of its Greater China healthcare practice, where he served leading pharmaceutical companies and hospital groups on strategic and operation improvement topics.
Dr. Tong holds a Ph.D. in Medical Pharmacology from David Geffen School of Medicine at University of California, Los Angeles, and a B.S. from Tsinghua University.